Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Earnings data Q3 2026

Earnings data Q4 2026

Earnings data Q1 2027

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Medtronic reports robust Q3 earnings, eyes growth in key segments

Medtronic's Q3 2025 performance reflects consistent revenue growth and notable strengths in key segments like Cardiac Ablation Solutions, Structural Heart, and Diabetes. Challenges in the Surgical segment and regulatory hurdles for the Hugo soft tissue robotic platform are being addressed, while opportunities in Hypertension treatment and Renal Denervation franchise offer growth potential. The company's focus on disciplined pricing, margin improvement, and mitigating FX risks align with its strategy for sustainable earnings growth. Guidance for FY '25 anticipates revenue and EPS growth acceleration in Q4, signaling positive momentum for investors and stakeholders.

Medtronic reports robust growth, plans Diabetes business separation for growth

Medtronic's strong financial performance, strategic focus on high-margin markets, and plans for business separation indicate a positive outlook. Despite challenges from tariffs and investment back-loading, the company is poised for growth through segment expansions and portfolio management strategies.

Medtronic surpasses Q1 expectations, eyes growth in key segments

Medtronic's Q1 performance exceeded expectations with positive growth across key segments Focus on innovation, efficiency, and governance enhancements to drive future growth Challenges include awaiting regulatory approvals and ensuring safety and efficacy standards Opportunities lie in continued growth acceleration, increased investments, and digital ecosystem expansion

Medtronic beats Q2 expectations, raises guidance for fiscal '26

Medtronic's Q2 performance exceeded expectations, driven by strong revenue growth in key segments. With increased guidance for fiscal '26, the company aims to sustain momentum and drive innovation. Challenges include maintaining growth acceleration amidst market dynamics and regulatory uncertainties.

Medtronic excels in Q3 earnings, poised for sustained growth

Medtronic's Q3 performance reflects financial strength and strategic focus on innovation and growth. While challenges exist in converting traction to procedures and managing tariffs, the company's commitment to sustained growth and disciplined execution is evident. Opportunities lie in leveraging successful launches, direct-to-consumer strategies, and investments for future expansion.